Lugui Qiu
YOU?
Author Swipe
View article: Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
PURPOSE Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BT…
View article: Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma
Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma Open
Monocyte‐derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune ev…
View article: BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)
BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002) Open
Background: Primary plasma cell leukemia (PPCL) is the most aggressive subtype of plasma cell neoplasms. Following the recent revision of diagnostic criteria by IMWG, the incidence of PPCL had approximately doubled. Despite this, prognosis…
View article: Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)
Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study) Open
Background: Marginal Zone Lymphoma (MZL) is a group of B-cell malignancies. Orelabrutinib (ORE), the first approved BTKi in China for patients after at least one treatment. This phase II trial evaluates the efficacy and safety of orelabrut…
View article: A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)
A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL) Open
Background: The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a transmembrane protein that is overexpressed in multiple cancers, including lymphomas. HDM2005 is an antibody-drug conjugate comprising a humanized IgG1 monoclonal …
View article: Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma
Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma Open
Background: Most anti-CD19 chimeric antigen receptor (CAR) T-cell products have the single-chain variable fragment (scFv) derived from the FMC63 monoclonal antibody. We developed a new hybridoma clone, HI19α, which binds to distinct epitop…
View article: Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma
Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma Open
Background: High-risk chromosomal abnormalities (HRCAs) detected by fluorescence in situ hybridization (FISH) have a well-established adverse prognostic impact in multiple myeloma (MM). It is increasingly recognized that the coexistence of…
View article: Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events
Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events Open
Importance Belantamab mafodotin (belamaf)‐containing regimens are effective treatment options for patients with relapsed and/or refractory multiple myeloma. Ocular events are a common adverse effect of belamaf treatment, which can be manag…
View article: Risk analysis of non-Hodgkin lymphoma (NHL) mortality associated with high body mass index (HBMI) in China: a population study
Risk analysis of non-Hodgkin lymphoma (NHL) mortality associated with high body mass index (HBMI) in China: a population study Open
Background : This study aims to explore the trend of NHL mortality caused by high body mass index (HBMI) in China from 1992 to 2021. Methods : The mortality data is obtained from the 2021 Global Burden of Disease (GBD). We used the Age-Per…
View article: Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing
Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing Open
Multiple myeloma (MM) shows inherent clinical and biological heterogeneity, leading to variable treatment responses and outcomes. The complex molecular landscape of MM makes precise risk stratification through clinical genetic testing diff…
View article: Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 5. Factors associated with progression.
View article: Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 6. The outcomes and disease status of patients who completed the treatment.
View article: Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 6. Swim lane plots of efficacy in patients treated with ZID.
View article: Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 4. Change of lymphocyte subsets before and after treatment.
View article: Supplementary Data 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Data 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Inclusion and exclusion criteria, Exclusion criteria, Treatment termination criteria and exclusion criteria, Case exclusion criteria, General combined medication and supportive care
View article: Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 1. Schematic diagram of the research scheme.
View article: Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 2. Treatment flow chart.
View article: Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 4. Factors associated with deep response rate after induction and at best response.
View article: Supplemental Figure 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 5. Survival outcomes in patients with or without deep remission.
View article: Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 3. Mutations and immunoglobulin heavy chain variable (IGHV) fragments of patients.